Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, France, China, Japan - Size and Forecast 2024-2028

Gastrointestinal Stromal Tumor (GIST) Therapeutics Market 2024-2028

The Gastrointestinal Stromal Tumor (GIST) Therapeutics Market size is estimated to grow by USD 1.02 billion, at a CAGR of 6.01% between 2023 and 2028. 

Gastrointestinal stromal tumour is an uncommon type of cancer; hence, the awareness of the disease is very low among people globally. As a result, the diagnosis of the indication is often delayed until the late stages due to the lack of knowledge of the symptoms, which leads to an increase in the challenges with the treatment. Therefore, the morbidity of the disease is high. To overcome this challenge, various organizations are conducting awareness campaigns at both the regional level and global levels. For instance, GIST Support International is an organization that focuses on bringing patients, families, and medical professionals together through various summits and social media platforms. Hence, the growth in the number of awareness campaigns is leading to the increasing diagnosis of the disease during the early stages, which is resulting in more patients undergoing treatment on time, thus driving the growth during the Market forecasting period.

Technavio has segmented the market into Distribution Channel, Route Of Administration and Geography

• The distribution channel segment is classified into hospital pharmacies, retail pharmacies, and online pharmacies
• The route of administration segment is classified into oral and parenteral
• The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes in-depth market trends and analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.

What will be the size of the Gastrointestinal Stromal Tumors Therapeutics Market During the Forecast Period?

To learn more about this report, Download Report Sample

Gastrointestinal Stromal Tumors Therapeutics Market Segmentation by Distribution Channel, Route Of Administration and Geography Analysis

Distribution Channel Analysis 

Hospital pharmacies

The market share growth by the hospital pharmacies segment will be significant during the forecast period. Hospital pharmacies serve as key intermediaries in the distribution of pharmaceuticals, including generics and other medications used to treat GIST. These pharmacies are integral in ensuring that prescribed medications, such as KEYTRUDA and OPDIVO, are readily available to healthcare professionals for the treatment of patients with GIST within the hospital setting.

Get a glance at the market contribution of various segments Download PDF Sample

The hospital pharmacies segment was the largest and was valued at USD 1.14 billion in 2018. Furthermore, hospital pharmacies contribute to patient education, offering guidance on medication adherence and potential drug interactions. The convenience of obtaining prescribed medications within the hospital setting enhances patient compliance with treatment regimens, which is crucial for the effective management of GIST. Hospital pharmacies thus act as a linchpin in facilitating the availability, accessibility, and proper utilization of medications for combating GIST conditions in healthcare settings worldwide. These factors will contribute to the growth of the hospital pharmacies segment, which will drive the growth of the market during the forecast period.

Route Of Administration Analysis

Oral

Currently, the oral segment is dominating the global gastrointestinal stromal tumors therapeutics market, primarily due to the presence of large pharmaceutical vendors such as Bayer, Novartis, and Pfizer with their specialty drugs for the treatment of the indication. Drugs such as STIVARGA by Bayer, GLEEVEC by Novartis, and SUTENT by Pfizer have gained popularity due to their ability to target multiple proteins in the body and inhibit the abnormal division of the cells in the body. However, the demand for these drugs is expected to remain higher than the generic drugs during the forecast period, which results in a partial offset of the damage caused by generics. Therefore, all these factors will lead to moderate growth of the oral segment of the global gastrointestinal stromal tumors therapeutics market during the forecast period.

Parenteral

The parenteral route involves the administration of drugs into the body through subcutaneous, intravenous, and intramuscular routes. The popularity of these drugs for the treatment of various cancer indications has led them to receive blockbuster status, which is expected to attract a major share of patients to undergo treatment using these drugs during the forecast period. The pipeline for the indication also witnesses the presence of cancer vaccines in the early stages of clinical trials. For instance, various other vendors in the early stages of the pipeline are developing novel therapies that are administered through the parenteral route. Although these drugs are not expected to receive marketing approval from the US FDA and the EMA during the forecast period, these drugs are expected to add significant value to the growth of the parenteral segment. Owing to the advances in research and the expected launch of novel drugs, the parenteral segment is expected to drive market growth during the forecast period. 

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional market growth analysis, market trends and drivers that will shape the market during the forecast period. The presence of the US, the world's largest pharmaceutical market in the region, is driving gastrointestinal stromal tumor therapeutics market growth in North America. Despite the heavy dominance of substitute treatment options such as surgery, the market in the region has witnessed an increase in the adoption of therapeutics for treating gastrointestinal stromal tumors in recent years. Furthermore, advanced healthcare infrastructure in the region is helping in the early diagnosis of the disease, which remained a major challenge to the growth of the gastrointestinal stromal tumor (GIST) therapeutics market in the past.

Also, the increasing number of patient assistance programs by companies is helping patients undergo treatment using therapeutics at an affordable price. The eligible patients will be given a Pfizer Oncology Together Co-Pay Savings Card, which provides them with a maximum benefit of USD 25,000 per year. Such patient assistance programs are helping to increase the adoption rate of therapeutics, thus driving the demand for GIST therapeutics. Owing to these factors, the gastrointestinal stromal tumor (GIST) therapeutics market in North America is expected to witness an accelerating growth momentum and remain the largest contributing region of the global market during the forecast period.

Buy Full Report Now

Key Gastrointestinal Stromal Tumors Therapeutics Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The market report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

Ascentage Pharma - The company offers gastrointestinal stromal tumour therapeutics such as Gleevec-resistant gastrointestinal stromal tumour.

• Bayer AG
• Blueprint Medicines Corp.
• Bristol Myers Squibb Co.
• Deciphera Pharmaceuticals Inc
• Mendus AB
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Xencor Inc.
• AB Science SA
• AROG Pharmaceuticals INC.
• Ipsen Pharma
• Theseus Pharmaceuticals.
• Daiichi Sankyo Co. Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Gastrointestinal Stromal Tumors Therapeutics Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market forecasting and growth. Our researchers analyzed the data with 2023 as the base year and explained market growth and forecasting, along with the key drivers, trends, and challenges. 

Key Gastrointestinal Stromal Tumors Therapeutics Market Drivers

The growing geriatric population is notably driving the market growth. Gastrointestinal stromal tumours are common in people aged 50 years and above; hence, the growing geriatric population globally is driving the gastrointestinal stromal tumour (GIST) therapeutics market growth. The risk of a person developing the disease increases with age. The advances in the healthcare infrastructure and the increasing treatment options for various indications, such as cancer, have increased the life expectancy of people globally. Also, factors such as the increasing awareness about various life-threatening indications have been contributing to the higher life expectancy.

However, as per the data collected by the World Bank Group and the NIH, globally, the proportion of the geriatric population is expected to grow further in the coming years. As the elderly population increases, the incidence of GIST, a cancer affecting the gastrointestinal tract, also rises. This demographic trend contributes to a higher demand for effective therapeutics, leading to the growth of the market during the forecast period. 

Significant Gastrointestinal Stromal Tumors Therapeutics Market Trends

Increasing research funding for GIST therapeutics is an emerging trend shaping the market growth. Currently, the global gastrointestinal stromal tumour therapeutics market has only three specialty drugs and limited chemotherapies approved for the treatment. Despite the low prevalence of the disease, the market witnesses a huge unmet need for therapeutics, largely due to the strong presence of the geriatric population. This is leading to various vendors and research institutes researching and developing novel therapies.

Moreover, the number of research grants for the development of therapies for gastrointestinal stromal tumours has increased in the last decade, and these funds are expected to result in the development of novel therapies, which will contribute to the growth of the market in focus during the forecast period.

Major Gastrointestinal Stromal Tumors Therapeutics Market Challenges

The low prevalence of GIST disease is a significant challenge hindering market growth. The global gastrointestinal stromal tumour therapeutics market faces a heavy threat from the low prevalence of the disease globally. The global prevalence of the indication is expected to be in the range of 1.1 people to 1.4 people per every 100,000 people, while the prevalence of the indication is higher in the European population, with the prevalence being approximately 1.7 to 2 people per every 100,000 people. The number of new cases of gastrointestinal stromal tumours in the US is estimated to be in the range of 3,300-6,000 cases per year. 

However, the low patient pool further poses a challenge for companies to conduct studies on developing novel therapies and successfully launching them in the market. Hence, the market has only a limited number of approved therapies for the treatment of the indication. This often results in a delay in the launch of drugs, leading to a high preference for alternative treatment options such as surgery. This is expected to pose a threat to the growth of the gastrointestinal stromal tumour therapeutics market during the forecast period.

Buy Now Full Report

Key Gastrointestinal Stromal Tumors Therapeutics Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. The market analysis and report focus on adoption rates in different regions based on penetration. Furthermore, the market research and growth report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Gastrointestinal Stromal Tumors Therapeutics Market Customer Landscape

Segment Overview

The gastrointestinal stromal tumours therapeutics market forecasting report, market growth by revenue at global, regional & country levels and provides an analysis of the latest market growth and trends and opportunities from 2018 to 2028. 

• Distribution Channel Outlook
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

• Route Of Administration Outlook
  • Oral
  • Parenteral

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina 
    • Australia 

Gastrointestinal Stromal Tumors Therapeutics Market Scope
Report Coverage	Details
Page number	165
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 6.01%
Market Growth 2024-2028	USD 1.02 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	5.46
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 41%
Key countries	US, UK, France, China, and Japan
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	Ascentage Pharma, Bayer AG, Blueprint Medicines Corp., Bristol Myers Squibb Co., Deciphera Pharmaceuticals Inc, Mendus AB, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Xencor Inc., AB Science SA, AROG Pharmaceuticals INC., Ipsen Pharma, Theseus Pharmaceuticals., Daiichi Sankyo Co. Ltd., Merck KGaA, and Takeda Pharmaceutical Co. Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Gastrointestinal Stromal Tumors Therapeutics Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the gastrointestinal stromal tumors therapeutics market between 2024 and 2028
• Precise estimation of the size of the gastrointestinal stromal tumors therapeutics market size and its contribution of the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of gastrointestinal stromal tumors therapeutics market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch